Geron (Nasdaq: GERN) granted inducement stock options effective March 17, 2026, to six newly hired employees totaling 956,250 shares.
The options carry an exercise price of $1.62 (the closing price on the grant date), a 10-year term, and vest over four years (12.5% at six months, remainder monthly over 42 months), granted under Nasdaq Rule 5635(c)(4) and Geron’s 2018 Inducement Award Plan.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
956,250 shares granted to attract six new hires
Options vest to align employee and shareholder interests over 4 years
Exercise price $1.62 tied to grant-date market price
Negative
Potential dilution from 956,250 option shares if exercised
Extended 10-year option term may delay cash proceeds realization
News Market Reaction – GERN
%
1 alert
%News Effect
-14.5%Trough Tracked
$1.04BMarket Cap
0.1xRel. Volume
On the day this news was published, GERN declined NaN%, reflecting a moderate negative market reaction.
Argus tracked a trough of -14.5% from its starting point during tracking.
Inducement option shares:956,250 sharesNew employees:6 employeesExercise price:$1.62 per share+5 more
8 metrics
Inducement option shares956,250 sharesAggregate stock options granted to six new employees
New employees6 employeesRecipients of inducement stock option grants
Exercise price$1.62 per shareEqual to GERN closing price on March 17, 2026 grant date
Option term10 yearsDuration of the newly granted stock options
Vesting period4 yearsOverall vesting duration for inducement options
Initial vesting tranche12.5% of sharesVests at six-month employment anniversary
Remaining vesting42 monthsEqual installments after initial 6‑month vesting
Inducement plan year2018Geron’s 2018 Inducement Award Plan governing these grants
Market Reality Check
Price:$1.2500Vol:Volume 10,935,219 vs 20-d...
low vol
$1.2500Last Close
VolumeVolume 10,935,219 vs 20-day average 19,809,480 (relative volume 0.55x).low
TechnicalPrice $1.62 trades above 200-day MA at $1.38, and about 19.4% below the 52-week high.
Peers on Argus
Peers show mixed moves: AVXL down 4.21%, while ZBIO, IMNM, QURE, and TSHA are mo...
Peers show mixed moves: AVXL down 4.21%, while ZBIO, IMNM, QURE, and TSHA are modestly positive (up to 2.07%). This dispersion suggests GERN’s action is more stock-specific than sector-driven.
2026 guidance for RYTELO revenue and operating expenses plus loan details.
Pattern Detected
Recent news, including earnings and guidance, often saw negative next-day reactions, even on seemingly constructive updates.
Recent Company History
Over the past few months, Geron has focused on commercialization of RYTELO and financial transparency. On Jan 12, 2026, it issued 2026 financial guidance, which saw a 6.72% positive reaction. Subsequent earnings-related items on Feb 11 and Feb 25 produced mild to sharp declines, with the full-year 2025 report followed by a -11.79% move. Routine items such as conference presentations and prior inducement grants also drew small negative reactions. Today’s inducement grants fit into this pattern of ongoing corporate and hiring activity.
Market Pulse Summary
This announcement details standard inducement stock option grants covering 956,250 shares at an exer...
Analysis
This announcement details standard inducement stock option grants covering 956,250 shares at an exercise price of $1.62, equal to the March 17, 2026 close. The options have a 10-year term and four-year vesting, with 12.5% vesting at six months and the remainder over 42 months. Contextually, Geron recently issued 2026 financial guidance and reported 2025 results, so investors may focus more on revenue, expenses, and execution while viewing these grants as routine hiring-related compensation.
"in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
stock optionsfinancial
"it granted stock options to purchase an aggregate of 956,250 shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise pricefinancial
"The stock options have an exercise price of $1.62 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"and vest over four years, with 12.5% of the shares underlying the options vesting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
compensation committeefinancial
"The equity awards were granted by the Compensation Committee of Geron’s Board"
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
inducement award planfinancial
"subject to the terms and conditions of Geron’s 2018 Inducement Award Plan"
An inducement award plan is a package of pay, often including stock options or restricted shares, granted to a new employee or executive to attract them to join a company — think of it like a signing bonus paid partly in company stock. Investors care because these awards increase compensation expense and can dilute existing shareholders’ ownership, affecting earnings per share and incentives that shape company strategy.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
FOSTER CITY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective March 17, 2026, it granted stock options to purchase an aggregate of 956,250 shares of common stock to six newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.
The stock options have an exercise price of $1.62 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.
The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under the plan.
About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.
CONTACT: Dawn Schottlandt Senior Vice President, Investor Relations and Corporate Affairs dschottlandt@geron.com
FAQ
What stock option inducement did Geron (GERN) grant on March 17, 2026?
Geron granted options for an aggregate of 956,250 shares to six new hires. According to the company, the options were effective March 17, 2026 and issued as inducement awards under Nasdaq Rule 5635(c)(4).
What are the terms of the Geron (GERN) inducement stock options granted March 17, 2026?
The options have a 10-year term, exercise price of $1.62, and vest over four years. According to the company, 12.5% vests at six months and remaining shares vest monthly over 42 months.
How might the March 17, 2026 GERN inducement grants affect shareholders?
If fully exercised, the grants could cause share dilution of 956,250 shares outstanding. According to the company, the awards are standard inducement options subject to the 2018 Inducement Award Plan.
Why did Geron (GERN) use inducement stock options for new employees on March 17, 2026?
Geron used inducement options to materially motivate new hires to join the company. According to the company, the awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
At what price can the March 17, 2026 Geron (GERN) options be exercised?
The exercise price is $1.62 per share, equal to the closing price on the grant date. According to the company, that price matches Geron's closing market price on the grant date.
